|Matthew Ringel MD, PhD
Ralph W. Kurtz Professor of Medicine, and Director of the Division of Endocrinology and Metabolism at The Ohio State University, OH, USA
Dr Ringel is the Co-Director of the Center for Cancer Engineering and Co-Leader of the Cancer Biology at Ohio State Comprehensive Cancer Center. He also serves as the Deputy Director of the OSU Center for Clinical and Translational Sciences. Dr Ringel’s NIH-funded laboratory is interested in defining the signaling pathways that regulate thyroid cancer progression and therapeutic resistance. His group’s work has focused on PI3 kinase/AKT and PAK signaling, metastasis-suppressing pathways, and transcriptional regulation of oncogenes in thyroid and other cancer types. He has an active clinical practice focused on thyroid cancer. He has been a member of the thyroid cancer NCCN guidelines committee, the National Cancer Institute Head and Neck Steering Committee, and currently is the co-Chair of the American Thyroid Association Thyroid Cancer Guidelines task force. To find out more about Professor Ringel and his vision for the journal please see here.
|A Beckers MD, PhD
Professor and Chief, Department of Endocrinology, University of Liège, Belgium
After completing his medical degree at the University of Louvain, Belgium, Professor Beckers undertook specialty training in Endocrinology, Internal Medicine and Nuclear Medicine. He oversees a Department with multiple clinical and research areas of interest, including pituitary tumors, thyroid disease, genetic causes of endocrine cancers and rare inherited syndromes. He has published more than 300 original articles. Research highlights include the original characterization and description of the syndrome, Familial Isolated Pituitary Adenomas and a newly described pediatric syndrome, X-Linked Acrogigantism. Professor Beckers has served two mandates as President of the Belgian Endocrine Society, has been the Secretary of the European NeuroEndocrine Association (ENEA), and has organised many national and international Congresses. Current research interests include the genetics of pituitary diseases, molecular and genetic investigation of rare disorders of endocrine development, gigantism and acromegaly and the study of new treatment options for aggressive endocrine tumors. He was awarded the 2016 Geoffrey Harris Prize of the European Society of Endocrinology (ESE), the most prestigious award from ESE, which is awarded in recognition of achievements by established researchers in the field of basic and clinical neuroendocrinology. In 2017, he was awarded the Rolf Gaillard Prize from ENEA. This is the most prestigious award of the ENEA and is awarded in recognition of outstanding lifetime contributions to the field of basic and clinical neuroendocrinology. Professor Beckers is a member of the Royal Academy of Medicine (Belgium) and is Doctor Honoris Causa of the Aix-Marseille University (France).
|J Cerutti PhD
Associate Professor of Genetics, Chief of the Genetics Division and Head of Genetic Bases of Thyroid Tumor Laboratory at Universidade Federal de São Paulo, Brazil
Associate Professor Cerutti is an elected member of the Executive Committee of the LATS and member of the board of Directors of Department of Thyroid of the Brazilian Endocrine Society. She was recipient of the Senior Investigator Award of LATS in 2015. Her primary interest lies on identification of genetic events implicated in the pathogenesis of pediatric and adult thyroid carcinomas. Her group is also employing mammalian cell models to functionally characterize the identified thyroid cancer-related genes. She is also devoted to refine genotype-phenotype correlations in MEN 2 patients.
|L Mulligan PhD
Professor, Cancer Research Institute at Queen’s University, Kingston, Canada
Professor Mulligan's research focuses broadly on regulation of cellular processes that contribute to neuroendocrine tumour growth and spread. Primary interests include intracellular protein localization and trafficking, mechanisms of cell motility and invasive spread, and regulation of receptor signalling in neuroendocrine cell models.
|H Sasano MD, PhD
Professor and Chairman, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
Professor Sasano is one of the leaders in the fields of endocrine action and metabolism in breast cancer, working particularly on the intracrine actions of both estrogens and androgens. He has contributed significantly to the recognition of the clinical importance of intratumoral estrogen production. He is the President of the Japanese Hormone and Cancer Society, and serves on the annual steering committee of The Endocrine Society and the WHO Endocrine Tumor Fascicle panel.
|W Tilley PhD
Director, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA, Australia
Professor Tilley is a cancer biologist and international expert in androgen receptor (AR) function in breast and prostate cancer. His laboratory has contributed to understanding the molecular mechanisms of resistance to hormonal therapies used in the treatment of prostate cancer. A current major research focus is the development of new treatments for prostate cancer that target the AR. His expertise spans the areas of steroid receptor structure and function, animal models of cancer, biomarkers, molecular biology, therapeutics and human explant cultures.
|R Clarke PhD, DSc
Co-Director of the Breast Cancer Research Program, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
Robert Clarke, PhD, DSc, is an internationally recognized leader in breast cancer research. Dr Clarke’s research applies cellular, molecular and computational methods to data from ongoing translational studies in both humans and experimental models to explore the mechanisms driving resistance to antihormone and cytotoxic therapies in breast cancer. He has developed a series of hormone resistant breast cancer models that are now widely used in the field. Dr Clarke and his colleagues have begun to identify components of the molecular signaling network that integrates cell stress signaling, protein misfolding, and communication among the endoplasmic reticulum, mitochondria and nucleus of breast cancer cells. Ultimately, this network determines if a breast cancer cell will proliferate, differentiate or die, and the mechanism by which the cell will die (apoptosis, autophagy, necrosis, senescence), in response to therapy. Dr Clarke serves on the editorial boards of several respected cancer journals. He has also served as chair of two NIH peer-review study sections (Basic Mechanisms of Cancer Therapeutics; National Center for Complementary and Alternative Medicine – Basic Science) and chaired multiple other peer-review panels. Dr Clarke is an elected Fellow of the Royal Society of Chemistry, a Fellow of the Royal Society of Medicine, and a Fellow of the Society of Biology in the UK.
|A Di Cristofano PhD
Professor of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, NY, USA
Professor Di Cristofano's general area of expertise is cancer biology and signaling. His work has made seminal contributions to the elucidation of the key role played by the PI3K signaling cascade in the pathogenesis of follicular and anaplastic thyroid cancer. His current research is focused on the identification of the genetic, metabolic, and signaling changes associated in vivo with thyroid cancer progression and resistance to therapy using sophisticated genetically modified mouse models.
|J Favier PhD
Research Professor, Head of the Genetics and Metabolism of Rare Cancers Laboratory, INSERM U970 – Paris-Cardiovascular Research Centre of the Georges Pompidou Hospital (HEGP), University Paris, Paris, France
Dr Favier’s primary interests are the fields of pheochromocytomas and paragangliomas and familial cancers associated with mitochondrial dysfunctions. She has a strong interest in mutations in genes encoding TCA cycle enzymes such as succinate dehydrogenase (SDH). Thanks to the wide collection of tumours of the COMETE network and to the unique experimental models generated in the lab, she has made pioneering discoveries in the field, demonstrating the links between SDH mutations and pseudo-hypoxia, epithelial-to-mesenchymal transition or epigenetic modifications. Dr Favier was the previous co-chair of the Pheochromocytoma Research Support Organization (PRESSOR).
|P Ghosh PhD
Associate Professor of Biochemistry and Molecular Medicine in the University of California Davis (UCD), CA, USA, with joint appointments in the Department of Urology, UCD, and the VA Northern California Health Care System
Paramita M Ghosh, PhD's expertise lies in the study of signal transduction pathways, especially related to prostate cancer. Dr Ghosh is a chartered member of the Basic Mechanisms in Cancer Therapeutics Study Section of the National Institutes of Health, and has also been a repeat reviewer for the Department of Defense Congressionally Directed Medical Research Programs. She is a member of the American Association for Cancer Research and her work has been awarded both at home and abroad.
|W W de Herder MD, PhD
Professor of Endocrine Oncology, Head of Education in Endocrinology and Head of the European Neuroendocrine Tumour Society (ENETS) Centre of Excellence for Neuroendocrine Tumors, Erasmus MC, Rotterdam, Netherlands
Professor de Herder’s major research interests are neuroendocrine and adrenal tumors/Cushing’s syndrome. He is a member of several international and Dutch national societies. He served as chairman and vice-chairman of ENETS as well as advisor of ENETS and North American Neuroendocrine Tumor Society (NANETS).
|D J Marsh PhD
Professor, Medical Science, and Head, Translational Oncology Group, University of Technology Sydney, Sydney, Australia
Professor Marsh’s primary interests are in the fields of Familial cancer and ovarian cancer. She has a strong interest in the genetics of endocrine disorders, most recently studying the tumour suppressor CDC73/HRPT2 shown to be a member of the human PAF1 complex with key transcriptional roles. Her work in ovarian cancer has included investigation of the role of hormonal influences, histone modifications and key pathways contributing to this malignancy.
|C J McCabe BSc, PhD
Professor of Molecular Endocrinology, Director of Postgraduate Research, School of Clinical and Experimental Medicine, University of Birmingham, UK
Professor McCabe works on mechanisms of endocrine cancers, including thyroid, breast, and head and neck tumour models. Specifically, the research of the McCabe group focuses on assessment of the role of the proto-oncogenes PTTG and PBF in thyroid, breast, head and neck, and colon tumours; in vitro and in vivo models exploring gene function and gene expression; mechanisms of aneuploidy and genetic instability; and the action of the sodium iodide symporter NIS in thyroid and breast tumours.
|J Ngeow MBBS, FRCP, MPH
Associate Professor, Genomic Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University, and Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore
Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. Dr Ngeow is funded by the National Medical Research Council and Ministry of Health Singapore to explore how gene-environmental interactions predisposes to cancer initiation and progression and the implementation of genomics into routine clinical care in Asia. She has active studies understanding the genetic basis of thyroid, breast and endometrial cancers, as well as soft tissue sarcomas.
|C Stratakis D(Med)Sc, MD
Scientific Director of National Institute of Child Health and Human Development, USA
Dr Stratakis is internationally recognized for his research on Cushing syndrome and other diseases, mentorship and leadership. His most recent work focuses on novel genes, such as GPR101 in gigantism, and succinate dehydrogenase (SDH) defects in a variety of tumors, including the dyad of paragangliomas and gastric stromal sarcomas or Carney-Stratakis syndrome. Dr Stratakis has received a number honours and awards internationally. He also served as Branch Chief and then Head of the largest Clinical Research program of NICHD (2003–2011), and Director of the NIH Paediatric Endocrinology Fellowship Program (2002–2014).
|F Weber MD
Professor of Surgery, University Hospital Essen, Department of General-, Visceral- and Transplantation Surgery, Essen, Germany
Professor Weber is responsible for the endocrine surgical program at the University Hospital Essen. His areas of expertise are endocrine oncology and endocrine tumor genetics. His primary areas of research are endocrine neoplasia and human cancer genetics. In addition, his research focuses on the elucidation of tumor-stroma interaction in visceral neoplasia.
Professor of Applied Statistics, Open University, UK
Professor McConway is research interests are in Bayesian methods and in applications of statistics in the life sciences (particularly ecology, evolution and clinical medicine). He studied at Cambridge, UCL and the Open University, and is currently a Vice-President of the Royal Statistical Society.
|N Bhowmick||USA||R Hicks||Australia||Y Rhee||Republic of Korea|
|M Campbell||USA||G Kaltsas||Greece||P W Rosario||Brazil|
|F Cetani||Italy||J Knauf||USA||P Santisteban||Spain|
|F Claessens||Belgium||A Lam||Australia||M Sarquis||Brazil|
|A Daly||Belgium||R Leung||USA||L Selth||Australia|
|S Dehm||USA||L B Mercado||Philippines||S Uchino||Japan|
|T Else||USA||N Mitsiades||Czech Republic||M Xing||USA|
|A Gill||Australia||L Murphy||Canada||M Zatelli||Italy|
|O Gimm||Sweden||N Nakagawa||Japan||A Zoubeidi||Canada|
|H Heemers||USA||F Pitoia||Argentina||W Zwart||Netherlands|
Editors' declarations are listed in the journal's Disclosure Policy